Development of a novel, low-cost, transdermal drug delivery patch with enhanced API stabilisation

开发一种新型、低成本、具有增强 API 稳定性的透皮给药贴片

• 批准号: 102864
• 金额: $ 27.01万
• 依托单位: AMAPHASE LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102864
• 关键词: Development; novel; low; cost; transdermal

Amaphase is developing a novel and versatile transdermal patch for use across multiple applications from pain relief to chronic skin conditions. Its patented technology allows Active Pharmaceutical Ingredients to be stabilised for long periods without the need for harmful preservatives and, once activated by the user, will facilitate deeper and more efficient delivery into the skin through an innovative sequence of materials science and chemistry-based events. The company has employed experienced industrial designers throughout the prototype development phase to work in parallel with the formulation of the chemistry to investigate and create solutions which enhance the whole user experience from first use to disposal. Maximising ease of use for self-care to achieve medicines adherence in an ageing population with chronic conditions poses a number of challenges, not least mobility, dexterity, strength, single handed application, removal and safe disposal. The aim is to take a fresh look at self-administered treatments where ease and simplicity of use will significantly contribute to the likelihood of market success.

Amaphase正在开发一种新型的多功能透皮贴片，用于从缓解疼痛到慢性皮肤状况的多种应用。其专利技术允许活性药物成分在不需要有害防腐剂的情况下长期稳定，一旦被用户激活，将通过创新的材料科学和化学事件序列促进更深入，更有效地输送到皮肤中。该公司在整个原型开发阶段都雇佣了经验丰富的工业设计师，与化学制剂并行工作，研究和创造解决方案，从第一次使用到处置，增强整个用户体验。在患有慢性疾病的老龄化人口中，最大限度地方便使用自我保健以实现药物依从性带来了许多挑战，尤其是机动性、灵活性、力量、单手应用、移除和安全处置。其目的是重新审视自我管理的治疗方法，其易用性和简单性将大大有助于市场成功的可能性。